erwinia asparaginase

Phase 3Protein / enzyme

erwinia asparaginase is one of 114 small molecule programs targeting Hematologic Malignancies. It is currently in Phase 3.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignanciesRecruiting

Acute Lymphoblastic Leukemia, PediatricActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Hematologic MalignanciesPhase 1

Recruiting

Acute Lymphoblastic Leukemia, PediatricPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

34 2

Xospata

Astellas

Phase 3

24 3

Fludara

Sanofi

Phase 3

17 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 5

Vepesid

AAvyxa

Phase 3

52 6

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 7

Vanflyta

Daiichi Sankyo

Phase 3

14 8

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 9

Cerubidine

HHikma Pharmaceuticals LLC

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05192889

Q2 2027

Phase 2Active, not recruiting

Acute Myeloid Leukemia

NCT03164057

Q3 2030

Phase 1Recruiting

Hematologic Malignancies

NCT05292664

Q4 2034

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia, Pediatric

NCT03020030

Clinical

Trials by Indication[1]

Lymphoblastic Lymphoma1 trial

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01451515·23 enrolled

Acute Lymphoblastic Leukemia1 trial

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05192889·35 enrolled

Refractory1 trial

A Study of Children With Refractory or Relapsed ALL

Completed·SSt. Jude Children's Research Hospital·Phase 3·NCT00187083·40 enrolled

Acute Myeloid Leukemia1 trial

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03164057·206 enrolled

Hematologic Malignancies1 trial

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting·—·Phase 1·NCT05292664·30 enrolled

2 more indications

Acute Lymphoblastic Leukemia, Pediatric1 trial

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruiting·DDana-Farber Cancer Institute·Phase 3·NCT03020030·560 enrolled

Leukemia, Acute Lymphoblastic1 trial

Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

Completed· Amgen logo

Amgen·Phase 3·NCT02393859·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for erwinia asparaginase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — erwinia asparaginase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for erwinia asparaginase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Amgen

erwinia asparaginase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2030

Q4 2034

Trials by Indication[1]

Lymphoblastic Lymphoma1 trial

Acute Lymphoblastic Leukemia1 trial

Refractory1 trial

Acute Myeloid Leukemia1 trial

Hematologic Malignancies1 trial

Acute Lymphoblastic Leukemia, Pediatric1 trial

Leukemia, Acute Lymphoblastic1 trial

References

Drug Info

Quick Facts

Related News